Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure

ÇAVUŞOĞLU Y., MERT K. U., Nadir A., MUTLU F., Morrad B., ULUS T.

JOURNAL OF CARDIOVASCULAR MEDICINE, vol.16, no.9, pp.603-609, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 9
  • Publication Date: 2015
  • Doi Number: 10.2459/jcm.0000000000000033
  • Journal Name: JOURNAL OF CARDIOVASCULAR MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.603-609
  • Keywords: acute heart failure, dobutamine, ivabradine, CORONARY-ARTERY-DISEASE, RATE REDUCTION, CONTROLLED-TRIAL, BETA-BLOCKERS, FUNNY CURRENT, RISK-FACTOR, OUTCOMES, MORTALITY, DEATH
  • Bezmialem Vakıf University Affiliated: Yes

Abstract

Background Ivabradine is a heart rate (HR)-lowering agent acting by inhibiting the I-f-channel. Dobutamine does increase the HR and has some deleterious effects on myocardium. So, we aimed to evaluate whether ivabradine treatment blunts a dobutamine-induced increase in HR.